Viewing Opinion | StockChase

Valeant Pharmaceuticals (VRX-T) opinion on 2018-06-12

Last Price Recorded: 32.2300 on 2018-06-20

ON STOCKCHASE SINCE Oct 2000

Consumer Products
Consumer Products
DON'T BUY

David Baskin
Valeant Pharmaceuticals was $34.650 at time of opinion
Owned : No

This is the Lazarus story of 2018, back from the dead. They are not anyones favorite stock. Even though they have sold off a lot of assets, they still have a lot of debt on their balance sheet and he called their profitability dubious, going forward. They have cleaned up a lot of their mess but they have a long way to go before becoming the kind of stock that he would consider for his type of portfolio. The debt burden in a rising interest rate environment, with many maturities that must be rolled over, poses too much risk.

UNKNOWN

All opinions for VRX-T (714)

127 BUY
19 BUY on WEAKNESS
71 COMMENT
261 DON'T BUY
30 HOLD
1 PARTIAL BUY
2 PARTIAL SELL
40 PAST TOP PICK
21 SELL
1 SPECULATIVE BUY
5 STRONG BUY
68 TOP PICK
26 WAIT
15 WATCH
27 WEAK BUY
View All

More experts covering VRX-T

SAVE
Add VRX-T to Watch List

All opinions for VRX-T (714)

127 BUY
19 BUY on WEAKNESS
71 COMMENT
261 DON'T BUY
30 HOLD
1 PARTIAL BUY
2 PARTIAL SELL
40 PAST TOP PICK
21 SELL
1 SPECULATIVE BUY
5 STRONG BUY
68 TOP PICK
26 WAIT
15 WATCH
27 WEAK BUY
View All

More experts covering VRX-T

SAVE
Add VRX-T to Watch List

Last 60 Days Opinions

No opinions for COMPANY TICKER in the last 60 days

No Comments.


You must be logged in to comment.

Successfully Saved Company